Overview

Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in Dialysis Patients

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Evaluate the Safety and Efficacy of Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in dialysis patients This study aimed to evaluate the effects of a topical cream containing Plectranthus amboinicus and Centella Asiatica when applied topically to diabetic foot ulcers in uremia patients with PAOD.
Phase:
Phase 4
Details
Lead Sponsor:
Cathay General Hospital
Collaborator:
Oneness Biotech Co., Ltd.